Reports indicate that unapproved, black market versions of the experimental weight loss drug retatrutide are linked to at least two deaths, prompting investigation by the Food and Drug Administration. This development highlights the risks associated with bypassing regulated drug development and manufacturing processes, a growing concern as demand for novel therapeutics increases. The FDA's increased scrutiny of these unregulated peptides suggests a potential shift in enforcement, and further investigation will be needed to determine the precise role of the counterfeit drug in these fatalities.
Read the full article at Futurism
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
Views20
Ali NematiBlogUI.author_articles
